BCR/ABL1–like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B-lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is characterized by a peculiar transcriptional profile that resembles that of true BCR/ABL1–positive cases, and have a heterogeneous genetic background and a poor outcome. Next-generation sequencing studies have demonstrated that the majority of patients carry rearrangements of tyrosine kinases or cytokine receptors and mutations of janus kinase (JAK)/signal transducer and activator of transcription (STAT), thus opening the way to the possible use of targeted therapeutic approaches. However, several issues remain unresolved at both the diagnostic and therapeutic level, such as the definition of a standardized method to identify BCR/ABL1–like ALL and the design of ad hoc clinical trials examining tyrosine kinase inhibitors or other tailored treatments. These aspects are discussed in this review.

BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? / Chiaretti, S.; Messina, M.; Foa, R.. - In: CANCER. - ISSN 0008-543X. - 125:2(2019), pp. 194-204. [10.1002/cncr.31848]

BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat?

Chiaretti S.;Messina M.;Foa R.
2019

Abstract

BCR/ABL1–like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B-lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is characterized by a peculiar transcriptional profile that resembles that of true BCR/ABL1–positive cases, and have a heterogeneous genetic background and a poor outcome. Next-generation sequencing studies have demonstrated that the majority of patients carry rearrangements of tyrosine kinases or cytokine receptors and mutations of janus kinase (JAK)/signal transducer and activator of transcription (STAT), thus opening the way to the possible use of targeted therapeutic approaches. However, several issues remain unresolved at both the diagnostic and therapeutic level, such as the definition of a standardized method to identify BCR/ABL1–like ALL and the design of ad hoc clinical trials examining tyrosine kinase inhibitors or other tailored treatments. These aspects are discussed in this review.
2019
acute lymphoblastic leukemia (ALL); BCR/ABL1–like; diagnosis; Ph–like; prognosis; tyrosine kinase inhibitors (TKIs)
01 Pubblicazione su rivista::01a Articolo in rivista
BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? / Chiaretti, S.; Messina, M.; Foa, R.. - In: CANCER. - ISSN 0008-543X. - 125:2(2019), pp. 194-204. [10.1002/cncr.31848]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1284012
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 44
social impact